Compare H2O America (HTO) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H2O America vs Novo Nordisk A/S — how do they compare? H2O America trades at $58.48 (market cap $2.43B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 68× H2O America's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold H2O America for 40 Days and Novo Nordisk A/S for 116 Days on average.
| HTO | NVO | |
|---|---|---|
Market Cap | $2.43B | $165.31B |
Volume | 593,883 | 11,432,838 |
Sector | Utilities | Health |
52-Week High | $65.43 | $63.98 |
52-Week Low | $44.44 | $35.29 |
Typical Hold Time | 40 Days | 116 Days |
Enterprise Value | $4.22B | $179.56B |
Dividend Yield | 3.03% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HTO trades at $58.07, up 0.16% with a bearish technical signal despite bullish oscillators. The company shows solid fundamentals with 12.91% net income margin and recent earnings beats in Q1 and Q2 2026. Recent acquisitions in Texas signal growth ambitions, though cash flow trends show heavy investing activity. Analyst consensus remains strongly bullish with 83% buy ratings and $66.50 price target.
The stock offers potential upside to analyst targets but faces execution risks from recent acquisitions and dilution concerns. Strong institutional interest from BlackRock and others supports the growth story, though technical weakness and high investing cash outflows warrant monitoring. The Dividend King status provides income stability amid expansion efforts.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
